Patents by Inventor Maria Obdulia Rabal Gracia
Maria Obdulia Rabal Gracia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11560407Abstract: The present invention provides peptides of general formula (I) and salts thereof, wherein: R1 and R2, taken together, form a birradical linker; and R2? is hydrogen; or, alternatively, R1 is selected from hydrogen, —C(?O)—CH2—NH—C(?O)—(C1-C5)alkyl, and —C(?O)—(C1-C20)alkyl; one of R2 and R2? is hydrogen and the other is selected from —C(?O)NR3R4, and —C(?O)OH; and R3 and R4 are same or different and are selected from hydrogen and (C1-C10)alkyl. These peptides are highly efficient in binding and inhibiting FoxP3, being efficient in inhibiting and blocking Treg cell functionality, which make them useful in the treatment of cancer. The present invention also provides constructs comprising the peptide of formula (I) as well as combinations comprising the peptide of formula (I), the construct or both.Type: GrantFiled: April 20, 2020Date of Patent: January 24, 2023Assignee: FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADAInventors: Inés Noelia Casares Lagar, Juan José Lasarte Sagastibelza, Teresa Lozano Moreda, Julen Oyarzabal Santamarina, Maria Obdulia Rabal Gracia
-
Publication number: 20200317733Abstract: The present invention provides peptides of general formula (I) and salts thereof, wherein: R1 and R2, taken together, form a birradical linker; and R2? is hydrogen; or, alternatively, R1 is selected from hydrogen, —C(?O)—CH2—NH—C(?O)—(C1-C5)alkyl, and —C(?O)—(C1-C20)alkyl; one of R2 and R2? is hydrogen and the other is selected from —C(?O)NR3R4, and —C(?O)OH; and R3 and R4 are same or different and are selected from hydrogen and (C1-C10)alkyl. These peptides are highly efficient in binding and inhibiting FoxP3, being efficient in inhibiting and blocking Treg cell functionality, which make them useful in the treatment of cancer. The present invention also provides constructs comprising the peptide of formula (I) as well as combinations comprising the peptide of formula (I), the construct or both.Type: ApplicationFiled: April 20, 2020Publication date: October 8, 2020Inventors: Inés Noelia CASARES LAGAR, Juan José LASARTE SAGASTIBELZA, Teresa LOZANO MOREDA, Julen OYARZABAL SANTAMARINA, Maria Obdulia RABAL GRACIA
-
Patent number: 10654896Abstract: The present invention provides peptides of general formula (I) and salts thereof, wherein: R1 and R2, taken together, form a birradical linker; and R2? is hydrogen; or, alternatively, R1 is selected from hydrogen, —C(?O)—CH2—NH—C(?O)—(C1-C5)alkyl, and —C(?O)—(C1-C20)alkyl; one of R2 and R2? is hydrogen and the other is selected from —C(?O)NR3R4, and —C(?O)OH; and R3 and R4 are same or different and are selected from hydrogen and (C1-C10)alkyl. These peptides are highly efficient in binding and inhibiting FoxP3, being efficient in inhibiting and blocking Treg cell functionality, which make them useful in the treatment of cancer. The present invention also provides constructs comprising the peptide of formula (I) as well as combinations comprising the peptide of formula (I), the construct or both.Type: GrantFiled: October 19, 2017Date of Patent: May 19, 2020Assignee: FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADAInventors: Inés Noelia Casares Lagar, Juan José Lasarte Sagastibelza, Teresa Lozano Moreda, Julen Oyarzabal Santamarina, Maria Obdulia Rabal Gracia
-
Publication number: 20190276496Abstract: The present invention provides peptides of general formula (I) and salts thereof, wherein: R1 and R2, taken together, form a birradical linker; and R2? is hydrogen; or, alternatively, R1 is selected from hydrogen, —C(?O)—CH2—NH—C(?O)—(C1-C5)alkyl, and —C(?O)—(C1-C20)alkyl; one of R2 and R2? is hydrogen and the other is selected from —C(?O)NR3R4, and —C(?O)OH; and R3 and R4 are same or different and are selected from hydrogen and (C1-C10)alkyl. These peptides are highly efficient in binding and inhibiting FoxP3, being efficient in inhibiting and blocking Treg cell functionality, which make them useful in the treatment of cancer. The present invention also provides constructs comprising the peptide of formula (I) as well as combinations comprising the peptide of formula (I), the construct or both.Type: ApplicationFiled: October 19, 2017Publication date: September 12, 2019Inventors: Inés Noelia CASARES LAGAR, Juan José LASARTE SAGASTIBELZA, Teresa LOZANO MOREDA, Julen OYARZABAL SANTAMARINA, Maria Obdulia RABAL GRACIA
-
Patent number: 10407423Abstract: It relates to the compounds of formula (I), or their pharmaceutically or veterinary acceptable salts, or their stereoisomers or mixtures thereof, wherein A, R1, R2, and R3 are as defined herein, which are inhibitors of one or more DNMTs selected from the group consisting of DNMT1, DNMT3A and DNMT3B. It also relates to pharmaceutical or veterinary compositions containing them, and to their use in medicine, in particular in the treatment and/or prevention of cancer, fibrosis and/or immunomodulation.Type: GrantFiled: November 15, 2016Date of Patent: September 10, 2019Assignee: FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADAInventors: Xabier Aguirre Ena, Julen Oyarzabal Santamarina, Felipe Prósper Cardoso, Maria Obdulia Rabal Gracia, Edurne San José Enériz, Juan Antonio Sánchez Arias
-
Publication number: 20190127354Abstract: It relates to the compounds of formula (I), or their pharmaceutically or veterinary acceptable salts, or their stereoisomers or mixtures of stereoisomers, wherein R is a radical selected from the group consisting of formula (A), formula (B), formula (C), formula (D), and formula (E), and R1, R2, and R3 are as defined herein, which are inhibitors of one or more DNMTs selected from the group consisting of DNMT1, DNMT3A and DNMT3B. It also relates to pharmaceutical or veterinary compositions containing them, and to their use in medicine, in particular in the treatment and/or prevention of cancer, fibrosis and/or immunomodulation.Type: ApplicationFiled: December 13, 2016Publication date: May 2, 2019Inventors: Xabier AGUIRRE ENA, Julen OYARZABAL SANTAMARINA, Felipe PRÓSPER CARDOSO, Maria Obdulia RABAL GRACIA, Edurne SAN JOSÉ ENÉRIZ, Juan Antonio SÁNCHEZ ARIAS
-
Publication number: 20180362525Abstract: It relates to the compounds of formula (I), or their pharmaceutically or veterinary acceptable salts, or their stereoisomers or mixtures thereof, wherein A, R1, R2, and R3 are as defined herein, which are inhibitors of one or more DNMTs selected from the group consisting of DNMT1, DNMT3A and DNMT3B. It also relates to pharmaceutical or veterinary compositions containing them, and to their use in medicine, in particular in the treatment and/or prevention of cancer, fibrosis and/or immunomodulation.Type: ApplicationFiled: November 15, 2016Publication date: December 20, 2018Inventors: Xabier AGUIRRE ENA, Julen OYARZABAL SANTAMARINA, Felipe PRÓSPER CARDOSO, Maria Obdulia RABAL GRACIA, Edurne SAN JOSÉ ENÉRIZ, Juan Antonio SÁNCHEZ ARIAS
-
Patent number: 9969744Abstract: Novel compounds for use in cognition improvement It relates to certain compounds having a polycyclic structure and a —(C?O)NRaRb moiety, wherein the polycyclic structure comprises at least three ring systems, wherein one ring system is a polycyclic ring system comprising from 2 to 4 rings; at least one ring is an aromatic ring; and wherein the structure comprises at least 3 nitrogen atoms and 1 oxygen atom. It also relates to pharmaceutical compositions containing them, and to their use in medicine, in particular in the treatment and/or prevention of neurological disorders coursing with a cognition deficit or impairment, or neurode-generative diseases.Type: GrantFiled: August 3, 2015Date of Patent: May 15, 2018Assignee: FUNDACIÓN LA INVESTIGACIÓN MÉDICA APLICADAInventors: María del Mar Cuadrado Tejedor, Ana María García Osta, Julen Oyarzabal Santamarina, Maria Obdulia Rabal Gracia, Juan Antonio Sánchez Arias, Ana Ugarte Baztán
-
Patent number: 9840500Abstract: It relates to the use of compounds of formula (I?), or their pharmaceutically or veterinary acceptable salts, or their stereoisomers or mixtures thereof, as anticancer agents and as agents for generating induced pluripotent stem cells. Compounds of formula (I?), wherein R2? is an alcoxy group, a hydrocarbon chain or a ring system, and R1, R3, and R4 are as defined herein, are dual inhibitors of histone methyltransferases and DNA methyltransferases. It also relates to the compounds of formula (I?), or their pharmaceutically or veterinary acceptable salts, or their stereoisomers or mixtures thereof, wherein R2? is phenyl or 5- to 6-membered heteroaromatic ring, both optionally fused to another rings (i.e., compounds of formula (I)). It also relates to pharmaceutical or veterinary compositions containing compounds of formula (I).Type: GrantFiled: March 30, 2015Date of Patent: December 12, 2017Assignee: FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADAInventors: Xabier Aguirre Ena, Julen Oyarzabal Santamarina, Felipe Prósper Cardoso, Maria Obdulia Rabal Gracia, Juan Roberto Rodríguez Madoz, Edurne San José Enériz
-
Publication number: 20170231931Abstract: The invention relates to a product that comprises a compound of formula (1-01) to (1-47) and a compound of formula (2-01) to (2-26), or their pharmaceutically or veterinary acceptable salts thereof, or any stereoisomers either of the compounds or of any of their pharmaceutically or veterinary acceptable salts. The invention also relates to said product for use in the treatment and/or prevention of a neurological disorder coursing with a cognition deficit or impairment, or a neurodegenerative disease.Type: ApplicationFiled: August 25, 2015Publication date: August 17, 2017Inventors: María del Mar CUADRADO TEJEDOR, Ana María GARCÍA OSTA, Julen OYARZABAL SANTAMARINA, Maria Obdulia RABAL GRACIA
-
Publication number: 20170217973Abstract: Novel compounds for use in cognition improvement It relates to certain compounds having a polycyclic structure and a —(C?O)NRaRb moiety, wherein the polycyclic structure comprises at least three ring systems, wherein one ring system is a polycyclic ring system comprising from 2 to 4 rings; at least one ring is an aromatic ring; and wherein the structure comprises at least 3 nitrogen atoms and 1 oxygen atom. It also relates to pharmaceutical compositions containing them, and to their use in medicine, in particular in the treatment and/or prevention of neurological disorders coursing with a cognition deficit or impairment, or neared-generative diseases.Type: ApplicationFiled: August 3, 2015Publication date: August 3, 2017Inventors: María del Mar CUADRADO TEJEDOR, Ana Maria GARCÍA OSTA, Julen OYARZABAL SANTAMARINA, Maria Obdulia RABAL GRACIA, Juan Antonio SÁNCHEZ ARIAS, Ana UGARTE BAZTÁN
-
Publication number: 20170121316Abstract: It relates to the use of compounds of formula (I?), or their pharmaceutically or veterinary acceptable salts, or their stereoisomers or mixtures thereof, as anticancer agents and as agents for generating induced pluripotent stem cells. Compounds of formula (I?), wherein R2? is an alcoxy group, a hydrocarbon chain or a ring system, and R1, R3, and R4 are as defined herein, are dual inhibitors of histone methyltransferases and DNA methyltransferases. It also relates to the compounds of formula (I?), or their pharmaceutically or veterinary acceptable salts, or their stereoisomers or mixtures thereof, wherein R2? is phenyl or 5- to 6-membered heteroaromatic ring, both optionally fused to another rings (i.e., compounds of formula (I)). It also relates to pharmaceutical or veterinary compositions containing compounds of formula (I).Type: ApplicationFiled: March 30, 2015Publication date: May 4, 2017Inventors: Xabier AGUIRRE ENA, Julen OYARZABAL SANTAMARINA, Felipe PRÓSPER CARDOSO, Maria Obdulia RABAL GRACIA, Juan Roberto RODRÍGUEZ MADOZ, Edurne SAN JOSÉ ENÉRIZ
-
Patent number: 9573956Abstract: It relates to certain compounds having a polycyclic structure and a hydroxamic acid moiety, wherein the polycyclic structure comprises at least three ring systems, wherein one ring system is a polycyclic ring system comprising from 2 to 4 rings; at least one ring is an aromatic ring; and wherein the structure comprises at least 3 nitrogen atoms and 1 oxygen atom. It also relates to a process for their preparation, as well as to pharmaceutical compositions containing them, and to their use in medicine, in particular in the treatment and/or prevention of neurological disorders coursing with a cognition deficit or impairment, or neurodegenerative diseases.Type: GrantFiled: February 27, 2014Date of Patent: February 21, 2017Assignee: FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADAInventors: María Del Mar Cuadrado Tejedor, Rafael Franco Fernández, Ana María García Osta, Julen Oyarzabal Santamarina, Maria Obdulia Rabal Gracia
-
Publication number: 20160002246Abstract: It relates to certain compounds having a polycyclic structure and a hydroxamic acid moiety, wherein the polycyclic structure comprises at least three ring systems, wherein one ring system is a polycyclic ring system comprising from 2 to 4 rings; at least one ring is an aromatic ring; and wherein the structure comprises at least 3 nitrogen atoms and 1 oxygen atom. It also relates to a process for their preparation, as well as to pharmaceutical compositions containing them, and to their use in medicine, in particular in the treatment and/or prevention of neurological disorders coursing with a cognition deficit or impairment, or neurodegenerative diseases.Type: ApplicationFiled: February 27, 2014Publication date: January 7, 2016Inventors: Maria Del Mar CUADRADO TEJEDOR, Rafael FRANCO FERNÁNDEZ, Ana Maria GARCÍA OSTA, Julen OYARZABAL SANTAMARINA, Maria Obdulia RABAL GRACIA
-
Publication number: 20100022769Abstract: The present invention describes the synthesis of the compounds of formulae (1), (2) and (3) in which m and n, which may be identical or different, may have the values 0, 2, 3, 4, 5 and 6; Z and Y, which may be identical or different, represent a nitrogenated cyclic system bonded by nitrogen or by one of the ring carbons or an NR1R2 system; and X is selected from the group consisting of hydrogen, C1-C12 alkyl, substituted alkyl, C3-C12 aryl, amino, alkylamino, nitro, hydroxy, alkoxy, halogen, carboxy or carboxamido. The use of the compounds of formulae (1), (2) and (3) as anti-HIV agents in the treatment of Acquired Immune Deficiency Syndrome (AIDS) is described.Type: ApplicationFiled: October 26, 2007Publication date: January 28, 2010Inventors: Jordi Teixidó Closa, José Ignacio Borrell Bilbao, Santiago Nonell Marrugat, Xavier Batllori Aguilá, Sofia Pettersson Salom, Laia Ros Blancó, Maria Obdulia Rabal Gracia, Violata Pérez Nueno, José Esté Araque, Imma Clotet Codina, Mercedes Armand Ugón, Ralmon Puig De La Bellacasa